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Abstract 
Background:  To determine the efficacy of oral 
Zinc Sulphate in treatment of recalcitrant common 
warts. 
Methods: In this randomized control trial 90 
patients with recalcitrant warts were randomly 
allocated to two groups by lottery method named 
Group A (Oral Zinc sulphate) and Group B 
(Placebo). Group A patients were given oral zinc 
sulphate in a dose of 10mg/kg to a maximum dose of 
600mg/day for two months. Group B received 
glucose tablets as placebo 
 Results: Out of 45 patients in oral zinc sulphate 
group, 28 (62.22%) patients had complete eradication 
or at least 75% reduction in number of warts noted at 
presentation. On the other hand in the placebo group 
only 2 (4.44%) patients had > 75% reduction in 
number of warts.In oral zinc sulphate group it was 
noted that only 6 (13.3%) patients had less than 50% 
reduction in no. of warts. 11 (24.4%) had 50-75% 
efficacy and majority 28 (62.2%) patients had > 75 % 
reduction in number of warts. In contrast, in the 
placebo group 33 patients (73.3%) had less than 50% 
reduction, followed by 10 (22.2%) patients having 50-
75% reduction and only 2 (4.4%) patients had > 75% 
reduction in no. of warts 
Conclusion: Warts are common viral infection of 
skin caused by Human Papilloma Virus. Despite 
various treatment options available at times warts  
become recalcitrant. Oral zinc sulphate is an 
effective treatment option for recalcitrant multiple 
viral warts. Being oral therapy it is easy to take with 
less frequent follow up visits required. 





Warts are common, benign and usually self limiting 
lesions caused by human papilloma viruses (HPV).1 
HPV can cause disease at any site in stratified 
squameous epithelium either keratinized (skin) or non 
keratinized (mucosa). Warts are broadly classified as 
cutaneous, oral, genital and laryngeal warts. Among 
cutaneous warts are common warts, plane warts, 
plantar warts, periungual and filliform warts.2Not all 
warts need treatment as many give little inconvenience 
and will resolve spontaneously.3,4,5 Different treatment 
options are available for warts which include duct tape 
occlusion, topical salicylic acid, glutaraldehyde, 
podophyllin and podophyllotoxin, 5-fluororacil, 
cryotherapy, electrocautery and curettage, imiquimod, 
photodynamic therapy, lasers and many others.6,7 
Among the systemic treatments documented are 
Cimetidine, Levamisol and Zinc sulphate.8Of the 
available treatment options none is uniformly effective 
or virucidal9. Their safety and efficacy have not been 
assessed in double blind controlled clinical trials. 
Cryotherapy, electrocautery and topical salicyclic acid 
are most commonly used treatment options but none 
without side effects. Electrocautery carries a risk of 
scarring, cryotherapy causes pain and salicylic acid is 
irritant on facial skin and may cause contact 
dermatitis. 5,10 
HPV infection does not induce inflammatory cytokines 
and therefore options aimed at modulating immune 
system and facilitating production of cytokines have 
been proposed11. One immunomodulatory approach 
involves prescribing oral zinc, a micronutrient that is 
necessary for normal functioning of cells.12 
Mun JH, et all showed complete resolution of warts in 
50% of patients with no serious side effects.11 Sadighha 
A in 2009 conducted a study showing a remarkable 
clearance rate of 76.9% in zinc sulphate treated 
patients versus 7.8% in placebo group.13 Raza N 
demonstrated that serum zinc levels were low in 
patients with persistent, progressive and recurrent 
viral warts. According to their study zinc levels were 
low in 56% of patients compared to 32% of control 
with a significant p value of 0.003.14. 
Oral zinc sulphate is not  being used locally for the 
treatment of recurrent viral warts. It is speculated that 
being an oral therapy it would be more convenient for 
patients, requiring lesser clinic visits as are required 
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for other available treatment options.  
 
Patients and Methods  
This comparative study was conducted in 
Dermatology Department of Pakistan Institution of 
Medical Sciences(PIMS) Islamabad, from June 2016 to 
Dec 2016. Sample size (n) 90 patients ,45 in each group.
 Patients of either gender between 18 and 65 
years of age having single or multiple common warts 
on extragenital skin that are resistant to salicylic acid , 
electrocautery and cryotherapy used for at least six 
months(recalcitrant) were included. 
Immunocompromised patients and those having co 
morbidities like hypertension, diabetes or any other 
known chronic illness were not included in the study. 
Pregnant and lactating women were also not included. 
Number and site of warts were noted. Patients were 
randomly allocated to Group A and Group B by 
lottery method. Oral zinc sulphate in a dose of 10 
mg/kg body weight upto a maximum of 600 mg/kg 
per day were given to group A for a period of two 
months. Group B received glucose tablets as 
placebo.Patients were reviewed after 4 weeks. Final 
outcome was seen at 8th week.  Confounding factors 
like age, gender and duration of warts were controlled 
by stratification. Comparison of efficacy in two groups 
was calculated by Chi-Square test. p value of < 0.05 
was considered as significant. 
 
Results 
Majority (54.4%) of the patients were from the age 
interval of 20 – 30 years (Table 1).Mean age of Group 
A was 22.02±5.864 years having minimum age of 18 
and maximum of 49 years. The mean age of placebo 
group was 22.96 years ±6.582 years having range of 18 
to 44 years .    According to gender distribution of 
the patients there were 23 (51.1%) males in group A 
(experimental group) and 21 (46.7%) in placebo group 
having almost equal distribution (Table 2). There was 
no main difference in average number of warts on 
presentation before treatment. The mean number of 
warts in Oral Zinc Sulphate group was 6.98±1.803 with 
a range of 2 to 13 warts and in placebo group it was 
6.73±1.405 ranging from 3 to 10. After 4 weeks of 
treatment total number of warts reduced to 4.24±1.209 
warts on average with a range of 1 to 7 warts in group 
A and in group B the number of warts reduced to 
5.49±1.272 warts on average ranging from 2 to 8 warts 
After 8 weeks of treatment the average number of 
warts reduced very significantly in oral zinc sulphate 
group to 1.73±1.452 warts with a range of 0 to 6 warts 
and in placebo group the average number of warts 
were noted to 4.29±1.160 warts with a range of 2 to 7 
warts .  The efficacy of the treatment was defined as at 
least 75% reduction in number of warts and it was 
noted that in oral zinc sulphate group majority of the 
patients had > 75% reduction in number of warts i.e. 
28 (62.22%) . In the placebo group majority of the 
patients 33 (73.3%) had less than 50% reduction (Table 
3).The cross tabulation with respect to gender shows 
that there was no significant (p-value > 0.05) 
association between gender and efficacy of drug . 
 
Table 1: Age distribution (n=90) 
Categorized age Frequency Percent 
Cumulative 
Percent 
< 20 34 37.8 37.8 
20 – 30 49 54.4 92.2 
30 – 40 3 3.3 95.6 
> 40 4 4.4 100.0 
Table 2: Distribution of gender in  
both groups 
Group Gender Frequency Percent 
Cumulative 
Percent 
Group A  
(Oral Zinc 
Sulphate) 
Male 23 51.1 51.1 
Female 22 48.9 100.0 
Total 45 100.0  
Group B  
(Placebo) 
Male 21 46.7 46.7 
Female 24 53.3 100.0 
Total 45 100.0  
 












< 50% 6 13.3 13.3 
50 - 75 % 11 24.4 37.8 
> 75 % 28 62.2 100.0 
Total 45 100.0  
Group B  
(Placebo) 
< 50% 33 73.3 73.3 
50 - 75 % 10 22.2 95.6 
> 75 % 2 4.4 100.0 
Total 45 100.0  
Discussion 
Warts are benign epithelial proliferations caused by 
human papillomavirus (HPV). More than 200 types of 
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HPV have been recognized.15 Common warts are the 
commonest type of warts in children and adults.1 
HPV is efficient at evading recognition. The virus can 
globally downregulate keratinocyte innate immune 
sensors and suppress the type I interferon response, 
which is critical for the control of viral infection. There 
is no viremia and no virus-induced cell death; hence, 
there is no inflammation or danger signal to the 
immune system.17Therefore, methods aim at 
modulating and enabling the immune system to detect 
and defend against this virus, can be a therapeutic 
option. One such option is oral zinc sulphate. Zinc is 
required for multiple cellular tasks, and especially the 
immune system depends on a sufficient availability of 
this essential trace element.18 
Thymulin which is a Thymus specific hormone binds 
to highly specific binding receptors on T cells, induces 
several T cell markers and promotes T cell functions 
including allogenic cytotoxicity, suppressor function 
and IL-2 production. Levels of Thymulin are 
significantly decreased in minor zinc deficiency. 
INF- ᵞ is a major component of Th1 response and it 
upregulates MHC I antigen expression. INF ᵞ is 
decreased in zinc deficiency.19 There are several 
other mechanisms by which zinc acts in boosting the 
immune system and enabling to counteract various 
bacterial and viral infections.19 Al Gurairi et al first 
conducted a randomized placebo controlled trial. He 
administered oral zinc sulphate in a dose of 10mg/Kg 
body weight for two months in patients with 
recalcitrant warts and showed a clearance rate of 87% 
versus no response in placebo group.20,21 Two placebo 
controlled RCTs showed remarkable CR rates: 
76.9%and 78.1% in the zinc sulphate treated group 
compared with 7.8%and 13% in the placebo group 
after 2 months of treatment.13,22Another randomized 
double-blind prospective study comparing the efficacy 
of oral zinc sulfate and cimetidine revealed a 62.5% CR 
in the zinc-treated group versus 0% in the cimetidine 
group.23Mun JH, et all showed complete resolution of 
warts in 50% of patients treated with oral zinc 
sulphate with no serious side effects.11  
Conclusion 
Oral zinc sulphate is an effective treatment option for 
recalcitrant multiple viral warts. Being oral therapy it 
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